spacer
home > white papers > Risk-Based Inspection Readiness: Reducing Headaches with Advanced Preparation - The Avoca Group
WHITE PAPERS
logo_The_Avoca_.jpg

The Avoca Group

phone (609) 252-9020
web http://theavocagroup.com/
email 179 Nassau St., Suite 3A, Princeton, NJ 08542

Risk-Based Inspection Readiness: Reducing Headaches with Advanced Preparation

So often, inspections are a major source of stress in the clinical trial environment. This is especially true when processes involved in preparing for an inspection are reactive. But, it doesn’t have to be that way. Using industry-leading practices and resources enables a proactive approach to mitigate—or even eliminate—the pain points associated with preparing for inspections.

The term “risk-based approach” encompasses all activities related to risk-based quality management (RBQM). RBQM is defined as a “systematic process put in place to identify, assess, control, communicate, and review the risks associated with the clinical trial during its lifecycle.


Risk-Based Inspection Readiness: Reducing Headaches with Advanced Preparation
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Withings Announces U-Scan - The World’s First Hands-free Connected Home Urine Lab

Issy-les-Moulineaux – January 3, 2023 Following four years of development, Withings, global leader in connected health is proud to announce U-Scan, a breakthrough in-home biomarker analysis platform. One of the company’s most technologically advanced devices to date, U-Scan is a miniaturized health lab that hygienically sits within any toilet bowl1 to unlock the wealth of health information in daily urine. U-Scan has already been recognized by the Consumer Technology Association as a CES 2023 Innovation Award honoree in three categories: Smart Home, Fitness & Sports, and Digital Health.
More info >>


White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement